QUEST PHARMATECH INC. PROVIDES CLINICAL TRIAL AND CORPORATE UPDATE

The Company's lead product candidate, SL017 Topical Gel, is currently undergoing two independent Phase I clinical trials, one for Actinic Keratosis (AK) at the University of Alberta Dermatological Centre and the second for acne and cosmetic hair removal at Innovaderm in Montréal. The AK trial has so far recruited eight of the required twelve patients. Preliminary analysis indicates that the drug and the treatment are well tolerated with no adverse events. Therapeutic efficacies of SL017 for AK indication are awaiting the biopsy results from the treated area. These results are anticipated by the end of this quarter.
CNW Group